- Home
- TPST
as 02-21-2025 4:00pm EST
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 40.4M | IPO Year: | N/A |
| Target Price: | $21.67 | AVG Volume (30 days): | 877.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $6.00 | Next Earning Date: | 03-18-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tempest Therapeutics Inc. News
TPST Breaking Stock News: Dive into TPST Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
GlobeNewswire
15 days ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
GlobeNewswire
3 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The Wall Street Journal
3 months ago
A ‘Reverse Aging’ Guru’s Trail of Failed Businesses
Simply Wall St.
3 months ago
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock
GlobeNewswire
3 months ago
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
3 months ago
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Compare TPST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TPST Tempest Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.